These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 12920570

  • 1. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E, Haun M, Grünewald K, Gastl G.
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
    Nachbaur D, Clausen J, Kircher B.
    Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
    [Abstract] [Full Text] [Related]

  • 4. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
    Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC.
    Bone Marrow Transplant; 2007 Jul; 40(2):137-43. PubMed ID: 17530007
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
    Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK, Oertel J, Nitsche A, Siegert W.
    Bone Marrow Transplant; 2003 Oct; 32(7):695-701. PubMed ID: 13130317
    [Abstract] [Full Text] [Related]

  • 6. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B, Kerridge I, Gilroy N, Huang G, Hertzberg M, Gottlieb D, Bradstock K.
    Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
    [Abstract] [Full Text] [Related]

  • 7. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 8. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 9. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease.
    Ruiz-Argüelles GJ, Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J.
    Am J Hematol; 2004 Apr 01; 75(4):200-4. PubMed ID: 15054809
    [Abstract] [Full Text] [Related]

  • 10. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.
    Br J Haematol; 2005 Aug 01; 130(3):394-403. PubMed ID: 16042689
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N.
    Bone Marrow Transplant; 2010 Mar 01; 45(3):534-42. PubMed ID: 19668235
    [Abstract] [Full Text] [Related]

  • 12. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.
    Biol Blood Marrow Transplant; 2009 Dec 01; 15(12):1587-95. PubMed ID: 19896083
    [Abstract] [Full Text] [Related]

  • 13. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
    Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B, Barkholt L, Ringdén O.
    Transplantation; 2006 Oct 15; 82(7):913-9. PubMed ID: 17038906
    [Abstract] [Full Text] [Related]

  • 14. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation.
    Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M, Solano C, Bargay J, Pérez-Simon J, León A, Sarrá J, Brunet S, de la Cámara R, alloPBSCT and Infectious/nonifectious Complications Subcommittees of the Grupo Español de Transplante Hematopoyético (GETH).
    Bone Marrow Transplant; 2001 Aug 15; 28(4):341-7. PubMed ID: 11571505
    [Abstract] [Full Text] [Related]

  • 15. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation.
    Martino R, Rovira M, Carreras E, Solano C, Jorge S, De La Rubia J, Caballero MD, de Oteyza JP, Zuazu J, Moraleda JM, Ojeda E, Ferrá C, Serrano D, De La Cámara R, Urbano-Ispízua A, Brunet S, AlloPBSCT and Infectious/Non-infectious Complications Subcommittes of the Grupo Español de Trasplante Hematopoyético (GETH).
    Haematologica; 2001 Oct 15; 86(10):1075-86. PubMed ID: 11602414
    [Abstract] [Full Text] [Related]

  • 16. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov 15; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

  • 17. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun 15; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 18. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.
    Frère P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E, Fillet G, Beguin Y.
    Bone Marrow Transplant; 2006 Feb 15; 37(4):411-8. PubMed ID: 16415900
    [Abstract] [Full Text] [Related]

  • 19. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
    Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P.
    Bone Marrow Transplant; 2006 Nov 15; 38(10):687-92. PubMed ID: 17001346
    [Abstract] [Full Text] [Related]

  • 20. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ.
    Biol Blood Marrow Transplant; 2006 Dec 15; 12(12):1326-34. PubMed ID: 17162215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.